Related Experiment Video
Updated: Jun 3, 2026
09:43
An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
Published on: March 30, 2018
Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes
1Department of Microbiology and Tumor Virology Program, Abramson, Comprehensive Cancer Center, University of Pennsylvania Medical School, Philadelphia, Pennsylvania 19104, USA.
Summary
Epstein-Barr virus (EBV) causes lifelong infections and is linked to B-cell lymphomas, especially in immunocompromised individuals. Understanding EBV
Area of Science:
- Virology
- Oncology
- Immunology
Background:
- Epstein-Barr virus (EBV), a human gamma-herpesvirus, establishes lifelong asymptomatic infections in healthy individuals.
- EBV is frequently associated with diverse B-cell lymphomas, particularly in immunocompromised patients.
- EBV-associated lymphoproliferative disorders exhibit clinical and molecular heterogeneity, with varying EBV-encoded latent antigen expression.
Purpose of the Study:
- To review the biology and pathogenesis of EBV-associated B-cell lymphomas.
- To explore the clinical implications of EBV in lymphoproliferative diseases.
- To highlight recent discoveries on EBV mechanisms in cancer progression for novel therapeutic strategies.
Main Methods:
- Review of existing literature on Epstein-Barr virus biology.
- Analysis of pathogenesis mechanisms in EBV-associated B-cell lymphomas.
- Discussion of clinical presentations and molecular heterogeneity.
Main Results:
- EBV-driven B-cell immortalization involves cooperative latent proteins perturbing cell signaling pathways.
- EBV utilizes sophisticated mechanisms during cancer progression.
- Differential expression of EBV latent antigens influences disease characteristics.
Conclusions:
- EBV plays a critical role in the development of various B-cell lymphomas.
- Understanding EBV's oncogenic mechanisms is key to developing targeted therapies.
- Further research into EBV-host interactions can inform clinical management of EBV-associated malignancies.
